Non-AIDS-defining cancers among HIV-infected people

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 10, 2012, Pages 1377-1388

  Pinzone, M R ^a   Fiorica, F ^b   Di Rosa, M ^a   Malaguarnera, G ^a   Malaguarnera, L ^a   Cacopardo, B ^a   Zanghi G ^a   Nunnari, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

Anal cancer; Colorectal cancer; HAART; HCC; HIV; Hodgkin's lymphoma; Lung cancer; NADCs

Indexed keywords

ALCOHOL CONSUMPTION; ANUS CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INVASION; CANCER RISK; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE FUNCTION TEST; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; MORBIDITY; NON AIDS DEFINING CANCER; NONHODGKIN LYMPHOMA; PAPILLOMAVIRUS INFECTION; PREVALENCE; REVIEW; RISK ASSESSMENT; SMOKING; UTERINE CERVIX CANCER; ANUS TUMOR; COLORECTAL TUMOR; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TUMOR; LUNG TUMOR; NEOPLASM;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANUS NEOPLASMS; CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASMS;

EID: 84871856374     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. PALELLA FJ, BAKER RK, MOORMAN AC, CHMIEL JS, WOOD KC, BROOKS JT, HOLMBERG SD; HIV OUTPATIENT STUDY INVESTIGATORS. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34. (Pubitemid 44306484)
2. NUNNARI G, LETO D, SULLIVAN J, XU Y, MEHLMAN KE, KULKOSKY J, POMERANTZ RJ. Seminal reservoirs during an HIV type 1 eradication trial. AIDS Res Hum Retroviruses 2005; 21: 768-775. (Pubitemid 41434181)
3. NUNNARI G, SULLIVAN J, XU Y, NYIRJESY P, KULKOSKY J, CAVERT W, FRANK I, POMERANTZ RJ. HIV type 1 cervicovaginal reservoirs in the era of HAART. AIDS Res Hum Retroviruses 2005; 21: 714-718. (Pubitemid 41254237)
4. NUNNARI G, XU Y, ACHEAMPONG EA, FANG J, DANIEL R, ZHANG C, ZHANG H, MUKHTAR M, POMERANTZ RJ. Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection. J Neurovirol 2005; 11: 319-328. (Pubitemid 41614511)
5. NUNNARI G, POMERANTZ RJ. IL-7 as a potential therapy for HIV-1-infected individuals. Expert Opin Biol Ther 2005; 5: 1421-1426. (Pubitemid 41579427)
6. KULKOSKY J, BOUHAMDAN M, GEIST A, NUNNARI G, PHINNEY DG, POMERANTZ RJ. Pathogenesis of HIV-1 infection within bone marrow cells. Leuk Lymphoma 2000; 37: 497-515. (Pubitemid 30219058)
7. POMERANTZ RJ, NUNNARI G. HIV and GB virus C-can two viruses be better than one? N Engl J Med 2004; 350: 963-965. (Pubitemid 38269270)
8. NUNNARI G, SMITH JA, DANIEL R. HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier. J Exp Clin Cancer Res 2008; 27: 3.
9. PINZONE MR, DI ROSA M, CACOPARDO B, NUNNARI G. HIV RNA Suppression and Immune Restoration: Can We Do Better? Clin Develop Immunol 2012, 515962.
10. NUNNARI G, COCO C, PINZONE MR, PAVONE P, BERRETTA M, DI ROSA M, SCHNELL M, CALABRESE G, CACOPARDO B. The role of micronutrients in the diet of HIV-1-infected individuals. Front Biosci (Elite Ed) 2012; 4: 2442-2456.
11. ARGYRIS EG, ACHEAMPONG E, NUNNARI G, MUKHTAR M, WILLIAMS KJ, POMERANTZ RJ. Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independentof lipid rafts. J Virol 2003; 77: 12140-12151. (Pubitemid 37339867)
12. NUNNARI G. Do Vgamma2Vdelta2 T cells influence HIV disease progression? Clin Infect Dis 2008; 46: 1473-1475. (Pubitemid 351589955)
13. CELESIA BM, ONORANTE A, NUNNARI G, MUGHINI MT, MAVILLA S, MASSIMINO SD, RUSSO R. Porphyria cutanea tarda in an HIV-1-infected patient after the initiation oftipranavir/ritonavir: case report. AIDS 2007; 21: 1495-1496. (Pubitemid 46988017)
14. NUNNARI G, NIGRO L, PALERMO F, LETO D, POMERANTZ RJ, CACOPARDO B. Reduction of serum melatonin levels in HIV-1-infected individuals' parallel disease progression: correlation with serum interleukin-12 levels. Infection 2003; 31: 379-382. (Pubitemid 38005366)
15. NUNNARI G, OTERO M, DORNADULA G, VANELLA M, ZHANG H, FRANK I, POMERANTZ RJ. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS 2002; 16: 39-45. (Pubitemid 34062180)
16. XU Y, KULKOSKY J, ACHEAMPONG E, NUNNARI G, SULLIVAN J, POMERANTZ RJ. HIV-1-mediated apoptosis of neuronal cells: Proximal molecular mechanisms of HIV-1-induced encephalopathy. Proc Natl Acad Sci USA 2004; 101: 7070-7075. (Pubitemid 38596444)
17. KULKOSKY J, NUNNARI G, OTERO M, CALAROTA S, DORNADULA G, ZHANG H, MALIN A, SULLIVAN J, XU Y, DESIMONE J, BABINCHAK T, STERN J, CAVERT W, HAASE A, POMERANTZ RJ. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis 2002; 186: 1403-1411. (Pubitemid 35286107)
18. WANG FX, XU Y, SULLIVAN J, SOUDER E, ARGYRIS EG, ACHEAMPONG EA, FISHER J, SIERRA M, THOMSON MM, NAJERA R, FRANK I, KULKOSKY J, POMERANTZ RJ, NUNNARI G. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115: 128-137. (Pubitemid 40385513)
19. DORNADULA G, NUNNARI G, VANELLA M, ROMAN J, BABINCHAK T, DESIMONE J, STERN J, BRAFFMAN M, ZHANG H, POMERANTZ RJ. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis 2001; 183: 1682-1687. (Pubitemid 32466709)
20. OTERO M, NUNNARI G, LETO D, SULLIVAN J, WANG FX, FRANK I, XU Y, PATEL C, DORNADULA G, KULKOSKY J, POMERANTZ RJ. Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Res Hum Retroviruses 2003; 19: 1097-1103. (Pubitemid 38037379)
21. SMITH JA, NUNNARI G, PREUSS M, POMERANTZ RJ, DANIEL R. Pentoxifylline suppresses transduction by HIV-1-based vectors. Intervirology 2007; 50: 377-386. (Pubitemid 350014922)
22. NUNNARI G, ARGYRIS E, FANG J, MEHLMAN KE, POMERANTZ RJ, DANIEL R. Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines. Virology 2005; 335: 177-184. (Pubitemid 40544907)
23. ARGYRIS EG, DORNADULA G, NUNNARI G, ACHEAMPONG E, ZHANG C, MEHLMAN K, POMERANTZ RJ, ZHANG H. Inhibition of endogenous reverse transcription of humanand nonhuman primate lentiviruses: potential for development of lentivirucides. Virology 2006; 353: 482-490. (Pubitemid 44397147)
24. CHEN K, HUANG J, ZHANG C, HUANG S, NUNNARI G, WANG FX, TONG X, GAO L, NIKISHER K, ZHANG H. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006; 80: 7645-7657. (Pubitemid 44092585)
25. NUNNARI G, NIGRO L, PALERMO F, ATTANASIO M, BERGER A, DOERR HW, POMERANTZ RJ, CACOPARDO B. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact Thelper 1 cytokine profile. Ann Intern Med 2003; 139: 26-30.
26. SIMARD EP, ENGELS EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 2010; 51: 957-962.
27. MARTELLOTTA F, BERRETTA M, VACCHER E, SCHIOPPA O, ZANET E, TIRELLI U. AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res 2009; 7: 634-638.
28. BERRETTA M, CINELLI R, MARTELLOTTA F, SPINA M, VACCHER E, TIRELLI U. Therapeutic approaches to AIDSrelated malignancies. Oncogene 2003; 22: 6646-6659.
29. NASTI G, MARTELLOTTA F, BERRETTA M, MENA M, FASAN M, DI PERRI G, TALAMINI R, PAGANO G, MONTRONI M, CINELLI R, VACCHER E, D'ARMINIO MONFORTE A, TIRELLI U; GICAT; ICONA. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003; 98: 2440-2446. (Pubitemid 37466659)
30. ENGELS EA, PFEIFFER RM, GOEDERT JJ, VIRGO P, MCNEEL TS, SCOPPA SM, BIGGAR RJ. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-1654. (Pubitemid 44162407)
31. NUNNARI G, BERRETTA M, PINZONE MR, DI ROSA M, CAPPELLANI A, BERRETTA S, TIRELLI U, MALAGUARNERA M, SCHNELL JM, CACOPARDO B. Hepatocellular carcinoma in HIV positive patients. Eur Rev Med Pharmacol Sci 2012; 16: 1257-1270.
32. MANI D, HAIGENTZ M, ABOULAFIA DM. Lung Cancer in HIV Infection. Clinical Lung Cancer 2012; 13: 6-13.
33. MARTIS N, MOUNIER N. Hodgkin Lymphoma in Patients with HIV Infection: A Review. Curr Hematol Malig Rep 2012; 7: 228-234.
34. MACHALEK DA, POYNTEN M, JIN F, FAIRLEY CK, FARNSWORTH A, GARLAND SM, HILLMAN RJ, PETOUMENOS K, ROBERTS J, TABRIZI SN, TEMPLETON DJ, GRULICH AE. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13: 487-500.
35. ZANET E, BERRETTA M, DI BENEDETTO F, TALAMINI R, BALLARIN R, NUNNARI G, BERRETTA S, RIDOLFO A, LLESHI A, ZANGHÌ A, CAPPELLANI A, TIRELLI U. Pancreatic Cancer in HIV-Positive Patients: A Clinical Case-Control Study. Pancreas 2012 (Epub ahead of print)
36. SILVERBERG MJ, CHAO C, LEYDEN WA, XU L, TANG B, HORBERG MA, KLEIN D, QUESENBERRY CP JR, TOWNER WJ, ABRAMS DI. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23: 2337-2345.
37. PATEL P, HANSON DL, SULLIVAN PS, NOVAK RM, MOORMAN AC, TONG TC, HOLMBERG SD, BROOKS JT; ADULT AND ADOLESCENT SPECTRUM OF DISEASE PROJECT AND HIV OUTPATIENT STUDY INVESTIGATORS. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-736. (Pubitemid 351717418)
38. ENGELS EA, BROCK MV, CHEN J, HOOKER CM, GILLISON M, MOORE RD. Elevated incidence of lung cancer among HIV-infected Individuals. J Clin Oncol 2006; 24: 1383-1388. (Pubitemid 46622002)
39. FRISCH M, BIGGAR RJ, ENGELS EA, GOEDERT JJ; AIDSCANCER MATCH REGISTRY STUDY GROUP. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285: 1736-1745. (Pubitemid 32259908)
40. BURGI A, BRODINE S, WEGNER S, MILAZZO M, WALLACE MR, SPOONER K, BLAZES DL, AGAN BK, ARMSTRONG A, FRASER S, CRUM NF. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104: 1505-1511. (Pubitemid 41356166)
41. CLIFFORD GM, POLESEL J, RICKENBACH M, DAL MASO L, KEISER O, KOFLER A, RAPITI E, LEVI F, JUNDT G, FISCH T, BORDONI A, DE WECK D, FRANCESCHI S, SWISS HIV COHORT. Cancer Risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-432. (Pubitemid 40528605)
42. GRULICH AE, VAN LEEUWEN MT, FALSTER MO, VAJDIC CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67. (Pubitemid 47017468)
43. SHIELS MS, COLE SR, KIRK GD, POOLE C. A metaanalysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52: 611-622.
44. BURKHALTER JE, SPRINGER CM, CHHABRA R, OSTROFF JS, RAPKIN BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res 2005; 7: 511-522. (Pubitemid 41600909)
45. CENTERS FOR DISEASE CONTROL AND PREVENTION. VITAL SIGNS: Current Cigarette Smoking Among Adults Aged-18 Years-United States, 2009. MMWR 2010; 59: 1135-1140.
46. CHATURVEDI AK, PFEIFFER RM, CHANG L, GOEDERT JJ, BIGGAR RJ, ENGELS EA. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21: 207-213. (Pubitemid 46036929)
47. SHIELS MS, COLE SR, MEHTA SH, KIRK GD. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr 2011; 55: 510-515.
48. SIGEL K, WISNIVESKY J, DUBROW R, JUSTICE A, GORDON K, BROWN ST, GOULET J, BUTT AA, CRYSTAL S, RIMLAND D, RODRIGUEZ-BARRADAS M, GIBERT C, PARK LS, CROTHERS K. HIV is an independent risk factor for incident lung cancer. AIDS 2012; 26: 1017-1025.
49. KIRK GD, MERLO C, O' DRISCOLL P, MEHTA SH, GALAI N, VLAHOV D, SAMET J, ENGELS EA. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45: 103-110. (Pubitemid 46984625)
50. WISTUBA II, BEHRENS C, MILCHGRUB S, VIRMANI AK, JAGIRDAR J, THOMAS B, IOACHIM HL, LITZKY LA, BRAMBILLA EM, MINNA JD, GAZDAR AF. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA 1998; 279: 1554-1559. (Pubitemid 28233011)
51. SHEBL FM, ENGELS EA, GOEDERT JJ, CHATURVEDI AK. Pulmonary infections and risk of lung cancer among persons with AIDS. J Acquir Immune Defic Syndr 2010; 55: 375-379.
52. GUIGUET M, BOUE F, CADRANEL J, LANG JM, ROSENTHAL E, COSTAGLIOLA D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10: 1152-1159.
53. REEKIE J, KOSA C, ENGSIG F, MONFORTE AD, WIERCINSKA-DRAPALO A, DOMINGO P, ANTUNES F, CLUMECK N, KIRK O, LUNDGREN JD, MOCROFT A. Relationship between current level of immunodeficiency and nonacquired immunodeficiency syndrome-defining malignancies. Cancer 2010; 116: 5306-5315.
54. CLIFFORD GM, LISE M, FRANCESCHI S, EGGER M, BOUCHARDY C, KOROL D, LEVI F, ESS S, JUNDT G, WANDELER G, FEHR J, SCHMID P, BATTEGAY M, BERNASCONI E, CAVASSINI M, CALMY A, KEISER O, SCHONI-AFFOLTER F, SWISS HIV COHORT STUDY. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 2012; 106: 447-452.
55. BEARZ A, VACCHER E, TALAMINI R, BERRETTA M, TIRELLI U. Comment on 'Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection'. Br J Cancer 2012; 106: 1899-1900.
56. BEDIMO RJ, MCGINNIS KA, DUNLAP M, RODRIGUEZ-BARRADAS MC, JUSTICE AC. Incidence of non-AIDSdefining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009; 52: 203-208.
57. BROCK MV, HOOKER CM, ENGELS EA. Delayed diagnosis and elevated mortality in an urban population with HIV and LC: implications for patient care. J Acquir Immune Defic Syndr 2006; 43: 47-55. (Pubitemid 44306487)
58. BIGGAR RJ, ENGELS EA, LY S, KAHN A, SCHYMURA MJ, SACKOFF J, VIRGO P, PFEIFFER RM. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39: 293-299. (Pubitemid 40923208)
59. D'JAEN G, PANTANOWITZ L, BOWER M, BUSKIN S, NEIL N, GRECO EM, COOLEY TP, HENRY D, STEM J, DEZUBE BJ, STEBBING J, ABOULAFIA DM. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010; 11: 396-404.
60. CHEMOTHERAPY FOR LUNG CANCER IN HIV-POSITIVE PATIENTS. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01296113. Accessed: September 2012.
61. EBBERT JO, YANG P, VACHON CM, VIERKANT RA, CERHAN JR, FOLSOM AR, SELLERS TA. Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 2003; 21: 921-926. (Pubitemid 46606453)
62. ELZI L, SPOERL D, VOGGENSPERGER J, NICCA D, SIMCOCK M, BUCHER HC, SPIRIG R, BATTEGAY M; SWISS HIV COHORT STUDY. A smoking cessation programme in HIV-infected individuals: a pilot study. Antivir Ther 2006; 11: 787-795. (Pubitemid 44497174)
63. VIDRINE DJ, ARDUINO RC, LAZEV AB, GRITZ ER. A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/AIDS. AIDS 2006; 20: 253-260.
64. GOMAA AI, KHAN SA, TOLEDANO MB, WAKED I, TAYIORROBINSON SD. Hepatocellular carcinoma: Epidemiology, risk factors, and pathogenesis. World J Gastroenterol 2008; 14: 4300-4308.
65. CLIFFORD GM, RICKENBACH M, POLESEL J, DAL MASO L, STEFFEN I, LEDERGERBER B, RAUCH A, PROBST-HENSCH NM, BOUCHARDY C, LEVI F, FRANCESCHI S; SWISS HIV COHORT. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22: 2135-2141.
66. ALTAVILLA G, CAPUTO A, LANFREDI M, PIOLA C, BARBANTI-BRODANO G, CORALLINI A. Enhancement of chimical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol 2000; 157: 1081-1089.
67. GIORDANO TP, KRAMER JR, SOUCHEK J, RICHARDSON P, EL-SERAG HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164: 2349-2354. (Pubitemid 39532246)
68. GUIGUET M, BOUE F, CADRANEL J, LANG JM, ROSENTHAL E, COSTAGLIOLA D; CLINICAL EPIDEMIOLOGY GROUP OF THE FHDH-ANRS CO4 COHORT. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDHANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10: 1152-1159.
69. BABU CK, SUWANSRINON K, BREN GD, BADLEY AD, RIZZA SA. HIV induces TRAIL sensitivity in hepatocytes. PLoS ONE 2009; 4: e4623.
70. SULKOWSKI MS, THOMAS DL, CHAISSON RE, MOORE RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80. (Pubitemid 30038386)
71. BRUNO R, SACCHI P, FILICE C, PUOTI M, FILICE G. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. J Acquir Immune Defic Syndr 2002; 30: 535-536.
72. GARCIA-SAMANIEGO J, RODRIGUEZ M, BERENGUER J, RODRIGUEZ-ROSADO R, CARBO J, ASENSI V, SORIANO V. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-183. (Pubitemid 32104826)
73. BERRETTA M, GARLASSI E, CACOPARDO B, CAPPELLANI A, GUARALDI G, COCCHI S, DE PAOLI P, LLESHI A, IZZI I, TORRESIN A, DI GANGI P, PIETRANGELO A, FERRARI M, BEARZ A, BERRETTA S, NASTI G, DI BENEDETTO F, BALESTRERI L, TIRELLI U, VENTURA P. Hepatocellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard. Oncologist 2011; 16: 1258-1269.
74. TAVIO M, GROSSI P, BACCARANI U, SCUDELLER L, PEA F, BERRETTA M, ADANI G, VIVARELLI M, RIVA A, TIRELLI U, BRESADOLA V, VIALE P, RISALITI A. HIV-infected patients and liver transplantation: who, when and why. Curr HIV Res 2011; 9: 120-127.
75. DI BENEDETTO F, BERRETTA M, DE RUVO N, TARANTINO G, D'AMICO G, BALLARIN R, IEMMOLO RM, GERUNDA GE. Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy? J Surg Oncol 2012; 105: 111-112.
76. DI BENEDETTO F, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, DI SANDRO S, BALLARIN R, CODELUPPI M, GUARALDI G, GERUNDA GE. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2008; 34: 422-427. (Pubitemid 351381293)
77. BERRETTA M, ZANET E, DI BENEDETTO F, SIMONELLI C, BEARZ A, MORRA A, BONANNO S, BERRETTA S, TIRELLI U. Unusual presentation of metastatic hepatocellular carcinoma in an HIV/HCV coinfected patient: case report and review of the literature. Tumori 2008; 94: 589-591.
78. DI BENEDETTO F, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, DI SANDRO S, QUINTINI C, CODELUPPI M, TIRELLI U, GERUNDA GE. Don't deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J Clin Oncol 2006; 24: e26-27.
79. DI BENEDETTO F, TARANTINO G, MONTALTI R, BALLARIN R, D'AMICO G, BERRETTA M, GERUNDA GE. Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up. Transpl Int 2011; 24: e97.
80. RIZZO L, CALVARUSO V, CACOPARDO B, ALESSI N, ATTANASIO M, PETTA S, FATUZZO F, MONTINERI A, MAZZOLA A, L'ABBATE L, NUNNARI G, BRONTE F, DI MARCO V, CRAXÌ A, CAMMÀ C. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronichepatitis C. Am J Gastroenterol 2011; 106: 2112-2120.
81. NUNNARI G, VANCHERI C, GILLI E, MIGLIORE S, PALERMO F, LA ROSA C, NICOTRA P, RUSSO R, CACOPARDO B. Circulating fibrocytes as a marker of liver fibrosis inchronic hepatitis C. Front Biosci (Elite Ed) 2010; 2: 1241-1245.
82. PINZONE MR, CELESIA BM, DI ROSA M, CACOPARDO B, NUNNARI G. Microbial translocation in chronic liver diseases. Int J Microbiol 2012; 2012: 694629.
83. NUNNARI G, SCHNELL MJ. MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection. Front Biosci (Schol Ed) 2011; 3: 1032-1037.
84. NUNNARI G, MONTINERI A, PORTELLI V, SAVALLI F, FATUZZO F, CACOPARDO B. The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Eur Rev Med Pharmacol Sci 2012; 16: 1013-106.
85. CACOPARDO B, CAMMA C, PETTA S, PINZONE MR, CAPPELLANI A, ZANGHI A, NICOLOSI A, NUNNARI G. Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. Front Biosci (Elite Ed) 2012; 4: 1276-1286.
86. CACOPARDO B, NUNNARI G, BENANTI F, CAPPELLANI A, ONORANTE A, CALTABIANO E, RUSSO R. Leukocyte interferon alpha early retreatment for Child A HCV genotype1b-infected cirrhotics intolerant to pegylated interferons. Infection 2009; 37: 210-215.
87. CACOPARDO B, NIGRO L, NUNNARI G, LA MEDICA G, CAPPELLANI A, PALERMO F, CAPPELLO E, RUSSO R. Association between raised IL-8 serum levels and resistance to combined peg-interferon plus ribavirin therapy in HCV+ active chronic hepatitis. Infez Med 2008; 16: 80-85. (Pubitemid 351976636)
88. CACOPARDO B, NUNNARI G, NIGRO L. Clearance of HCV RNA following acute hepatitis A superinfection. Dig Liver Dis 2009; 41: 371-374.
89. JEMAL A, SIEGEL R, XU J, WARD E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
90. YEGUEZ JF, MARTINEZ SA, SANDS DR, SANDS LR, HELLINGER MD. Colorectal malignancies in HIVpositive patients. Am Surg 2003; 69: 981-987.
91. CHAPMAN C, ABOULAFIA DM, DEZUBE BJ, PANTANOWITZ L. Human Immunodeficiency Virus-Associated Adenocarcinoma of the Colon: Clinicopathologic Findings and Outcome. Clin Colorectal Cancer 2009; 8: 215-219.
92. FRISCH M, BIGGAR RJ, ENGELS EA, GOEDERT JJ; AIDSCANCER MATCH REGISTRY STUDY GROUP. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285: 1736-1745. (Pubitemid 32259908)
93. REINHOLD JP, MOON M, TENNER CT, POLES MA, BINI EJ. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol 2005; 100: 1805-1812. (Pubitemid 41648437)
94. BERRETTA M, TIRELLI U. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol 2006; 101: 907.
95. BERRETTA M, LLESHI A, CAPPELLANI A, BEARZ A, SPINA M, TALAMINI R, CACOPARDO B, NUNNARI G, MONTESARCHIO V, IZZI I, LANZAFAME M, NASTI G, BASILE F, BERRETTA S, FISICHELLA R, SCHIANTARELLI C, GARLASSI E, RIDOLFO A, GUELLA L, TIRELLI U. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr HIV Res 2010; 8: 218-222.
96. BERRETTA M, DI BENEDETTO F, BEARZ A, SIMONELLI C, MARTELLOTTA F, DEL BEN C, BERRETTA S, SPINA M, TIRELLI U. FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. Cancer Invest 2008; 26: 610-614. (Pubitemid 351918581)
97. BERRETTA M, CAPPELLANI A, DI BENEDETTO F, LLESHI A, TALAMINI R, CANZONIERI V, ZANET E, BEARZ A, NASTI G, LACCHIN T, BERRETTA S, FISICHELLA R, BALESTRERI L, TORRESIN A, IZZI I, ORTOLANI P, TIRELLI U. Clinical Presentation and Outcome of Colorectal Cancer in HIV-Positive Patients: A Clinical Case-Control Study. Onkologie 2009; 32: 319-324.
98. BINI EJ, GREEN B, POLES MA. Screening colonoscopy for the detection of neoplastic lesions in asymptomatic HIV-infected subjects. Gut 2009; 58: 1129-1134.
99. BERRETTA M, MARTELLOTTA F, SIMONELLI C, DI BENEDETTO F, DE RUVO N, DRIGO A, BEARZ A, SPINA M, ZANET E, BERRETTA S, TIRELLI U. Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report. J Chemother 2007; 19: 343-346. (Pubitemid 47075133)
100. BERRETTA M, DI BENEDETTO F, SIMONELLI C, BEARZ A, BERRETTA S, MAUGERI D, TIRELLI U. Multidisciplinary approach in a HIV/HCV-positive patient with liver metastases by colorectal cancer in the HAART era. Ann Oncol 2006; 17: 1333-1334. (Pubitemid 44288227)
101. BERRETTA M, LLESHI A, ZANET E, BEARZ A, SIMONELLI C, FISICHELLA R, NASTI G, BERRETTA S, TIRELLI U. Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. Onkologie 2008; 31: 394-397. (Pubitemid 351967578)
102. DI BENEDETTO F, DE RUVO N, BERRETTA M, MASETTI M, CAUTERO N, QUINTINI C, MONTALTI R, GUARALDI G, TIRELLI U, GERUNDA GE. Liver resection of metastasis by colorectal cancer in a HIV patient. Dig Liv Dis 2006; 38: 149-150. (Pubitemid 44356145)
103. BERRETTA M, ZANET E, TAIBI R, MARTELLOTTA F, PAVONE P, BEARZ A, GOBITTI C, CIANCIA EM, CANZONIERI V, TIRELLI U. Leiomyosarcoma of the parotid gland in an HIV-positive patient: therapeutic approach, clinical course and review of the literature. J Chemother 2009; 21: 215-218.
104. BERRETTA M, ZANET E, BASILE F, RIDOLFO AL, DI BENEDETTO F, BEARZ A, BERRETTA S, NASTI G, TIRELLI U. HIV-positive patients with liver metastases from colorectal cancer deserve the same therapeutic approach as the general population. Onkologie 2010; 33: 203-204.
105. BIGGAR RJ, JAFFE ES, GOEDERT JJ, CHATURVEDI A, PFEIFFER R, ENGELS EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108: 3786-3791. (Pubitemid 44864560)
106. BOHLIUS J, SCHMIDLIN K, BOUÉ F, FÄTKENHEUER G, MAY M, CARO-MURILLO AM, MOCROFT A, BONNET F, CLIFFORD G, PAPARIZOS V, MIRO JM, OBEL N, PRINS M, CHÊNE G, EGGER M; COLLABORATION OF OBSERVATIONAL HIV EPIDEMIOLOGICAL RESEARCH EUROPE. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood 2011; 117: 6100-6108.
107. POWLES T, ROBINSON D, STEBBING J, SHAMASH J, NELSON M, GAZZARD B, MANDELIA S, MØLLER H, BOWER M. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-890.
108. HERNDIER BG, SANCHEZ HC, CHANG KL, CHEN YY, WEISS LM. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease. Am J Pathol 1993; 142: 1073-1079. (Pubitemid 24060583)
109. RIGHETTI E, BALLON G, OMETTO L, CATTELAN AM, MENIN C, ZANCHETTA M, CHIECO-BIANCHI L, DE ROSSI A. DYNAMICS OF EPSTEIN-BARR VIRUS IN HIV-1-infected subjects on highly active antiretroviral therapy. AIDS 2002; 16: 63-73. (Pubitemid 34062183)
110. VACCHER E, SPINA M, TIRELLI U. Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals. Eur J Cancer 2001; 37: 1306-1315. (Pubitemid 32553775)
111. SPINA M, CARBONE A, GLOGHINI A, SERRAINO D, BERRETTA M, TIRELLI U. Hodgkin's Disease in Patients with HIV Infection. Adv Hematol 2011; 2011. pii: 402682.
112. SPINA M, BERRETTA M, TIRELLI U. Hodgkin's disease in HIV. Hematol Oncol Clin North Am 2003; 17: 843-858. (Pubitemid 36807600)
113. HOFFMANN C, CHOW KU, WOLF E, FAETKENHEUER G, STELLBRINK HJ, VAN LUNZEN J, JAEGER H, STOEHR A, PLETTENBERG A, WASMUTH JC, ROCKSTROH J, MOSTHAF F, HORST HA, BRODT HR. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 2004; 125: 455-462. (Pubitemid 38916190)
114. BERENGUER J, MIRALLES P, RIBERA JM, RUBIO R, VALENCIA E, MAHILLO B, PINTADO V, PALACIOS R, MONTES ML, TÉLLEZ MJ, LA CRUZ J, TORRE-CISNEROS J, RODRÍGUEZ-ARRONDO F, SEPÚLVEDA MA, GUTIÉRREZ F, PERALTA G, BOIX V. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47: 422-428. (Pubitemid 351366959)
115. XICOY B, RIBERA JM, MIRALLES P, BERENGUER J, RUBIO R, MAHILLO B, VALENCIA ME, ABELLA E, LÓPEZGUILLERMO A, SUREDA A, MORGADES M, NAVARRO JT, ESTEBAN H; GESIDA GROUP; GELCAB GROUP. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007; 92: 191-198.
116. LEVINE AM, LI P, CHEUNG T, TULPULE A, VON ROENN J, NATHWANI BN, RATNER L. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multiinstitutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24: 444-450.
117. HARTMANN P, REHWALD U, SALZBERGER B, FRANZEN C, SIEBER M, WÖHRMANN A, DIEHL V. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 2003; 14: 1562-1569. (Pubitemid 37304614)
118. SPINA M, GABARRE J, ROSSI G, FASAN M, SCHIANTARELLI C, NIGRA E, MENA M, ANTINORI A, AMMASSARI A, TALAMINI R, VACCHER E, DI GENNARO G, TIRELLI U. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100: 1984-1988. (Pubitemid 35001227)
119. SPINA M, ROSSI G, ANTINORI A. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HDHIV)-ASCO. J Clin Oncol 2007; 25(18 S): 8083.
120. SPINA M, CHIMIENTI E, MARTELLOTTA F, VACCHER E, BERRETTA M, ZANET E, LLESHI A, CANZONIERI V, BULIAN P, TIRELLI U. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 2010; 116: 1495-1501.
121. DI BENEDETTO F, DI SANDRO S, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, BALLARIN R, COCCHI S, POTENZA L, LUPPI M, GERUNDA GE. Kaposi's sarcoma after liver transplantation. J Cancer Res Clin Oncol 2008; 134: 653-658. (Pubitemid 351506416)
122. SIMONELLI C, TEDESCHI R, GLOGHINI A, TALAMINI R, BORTOLIN MT, BERRETTA M, SPINA M, MORASSUT S, VACCHER E, DE PAOLI P, CARBONE A, TIRELLI U. Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J Med Virol 2009; 81: 888-896.
123. BORTOLIN MT, SIMONELLI C, ZANUSSI S, PRATESI C, BIDOLI E, RUPOLO M, BERRETTA M, TEDESCHI R, DE PAOLI P. Effects on virological and immunological parameters during CD34 mobilization in HIV patients with lymphoma. Am J Hematol 2006; 81: 800-802. (Pubitemid 44536749)
124. KRISHNAN A, MOLINA A, ZAIA J, SMITH D, VASQUEZ D, KOGUT N, FALK PM, ROSENTHAL J, ALVARNAS J, FORMAN SJ. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005; 105: 874-878. (Pubitemid 40070778)
125. RE A, MICHIELI M, CASARI S, ALLIONE B, CATTANEO C, RUPOLO M, SPINA M, MANUELE R, VACCHER E, MAZZUCATO M, ABBRUZZESE L, FERREMI P, CAROSI G, TIRELLI U, ROSSI G. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114: 1306-1313.
126. ZANET E, BERRETTA M, MARTELLOTTA F, CACOPARDO B, FISICHELLA R, TAVIO M, BERRETTA S, TIRELLI U. Anal Cancer: Focus on HIV-Positive Patients in the HAART Era. Curr HIV Res 2011; 9: 70-81.
127. D'SOUZA G, WILEY DJ, LI X, CHMIEL JS, MARGOLICK JB, CRANSTON RD, JACOBSON LP. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48: 491-499.
128. WATSON AJ, SMITH BB, WHITEHEAD MR, SYKES PH, FRIZELLE FA. Malignant
129. MARTELLOTTA F, BERRETTA M, CACOPARDO B, FISICHELLA R, SCHIOPPA O, ZANGHÌ A, SPARTÀ D, CAPPELLANI A, TALAMINI R, IZZI I, RIDOLFO A, TORRESIN A, FIORICA F, TIRELLI U. Clinical presentation and outcome of squamous cell carcinoma of the anus in HIV-infected patients in the HAART-era: a GICAT experience. Eur Rev Med Pharmacol Sci 2012; 16: 1283-1291.
130. PIKETTY C, DARRAGH TM, DA COSTA M, BRUNEVAL P, HEARD I, KAZATCHKINE MD, PALEFSKY JM. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138: 453-459.
131. HOLLY EA, RALSTON ML, DARRAGH TM, GREENBLATT RM, JAY N, PALEFSKY JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001; 93: 843-849. (Pubitemid 32586612)
132. PIKETTY C, SELINGER-LENEMAN H, GRABAR S, DUVIVIER C, BONMARCHAND M, ABRAMOWITZ L, COSTAGLIOLA D, MARY-KRAUSE M; FHDH-ANRS CO 4. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22: 1203-1211.
133. CHIN-HONG PV, PALEFSKY JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002; 35: 1127-1134. (Pubitemid 35239474)
134. PARK IU, PALEFSKY JM. Evaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with Men. Curr Infect Dis Rep 2010; 12: 126-133.
135. FOX PA, NATHAN M, FRANCIS N, SINGH N, WEIR J, DIXON G, BARTON SE, BOWER M. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIVpositive MSM on HAART, with long-term followup data including the use of open-label imiquimod. AIDS 2010; 24: 2331-2335.
136. LAM JM, HOCH JS, TINMOUTH J, SANO M, RABOUD J, SALIT IE. Cost-effectiveness of screening for anal precancers in HIV-positive men. AIDS 2011; 25: 635-642.
137. BERRY JM, PALEFSKY JM, JAY N, CHENG SC, DARRAGH TM, CHIN-HONG PV. Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum 2009; 52: 239-247.
138. KREIMER AR, GONZALEZ P, KATKI HA, PORRAS C, SCHIFFMAN M, RODRIGUEZ AC, SOLOMON D, JIMENEZ S, SCHILLER JT, LOWY DR, VAN DOORN LJ, STRUIJK L, QUINT W, CHEN S, WACHOLDER S, HILDESHEIM A, HERRERO R; CVT VACCINE GROUP. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011; 12: 862-870.
139. KIM JJ, GOLDIE SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339: b3884.
140. KIM JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010; 10: 845-852.
141. WILKIN T, LEE JY, LENSING SY, STIER EA, GOLDSTONE SE, BERRY JM, JAY N, ABOULAFIA D, COHN DL, EINSTEIN MH, SAAH A, MITSUYASU RT, PALEFSKY JM. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202: 1246-1253.